• Tenax Therapeutics’ third-quarter 2026 net loss widened 6% year over year to $16.7 million.
• Research and development expenses rose 17% to $12.1 million, while selling, general and administrative expenses fell 12% to $5.7 million year over year.
• Cash and cash equivalents totaled $113.7 million at September 30, 2026, with operations expected to be funded through FY28.
• Enrollment in LEVEL-2 remains temporarily paused while a protocol amendment targets patients more likely to benefit from levosimendan.
• LEVEL missed its primary endpoint; the FDA granted a Type C meeting to discuss levosimendan development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-448517), on November 05, 2026, and is solely responsible for the information contained therein.